Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Madrid
Clinical trial register · Spain

Clinical Trials in Madrid, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Madrid 59 Barcelona 57 Valencia 23 Seville 22 L'Hospitalet de Llobregat 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca183 Janssen Research & Development, LLC109 Merck Sharp & Dohme LLC106 Novartis Pharmaceuticals100 Hoffmann-La Roche92 Clear sponsor filter
Site location
Madrid59 Barcelona57 Valencia23 Seville22 L'Hospitalet de Llobregat19
All 62 locations
Target enrolment
to

Trials with a site in Madrid

59 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
L'Hospitalet de Llobregat, Madrid, Seville
2026-07-02
Recruiting
Pfizer
Phase 3
954
Madrid, A Coruña, Pozuelo de Alarcón, Seville
2026-06-10
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
DrugsPF-08634404·Nivolumab
Pfizer
Phase 2/3
840
Barcelona, Madrid, Ourense
2026-05-14
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Barcelona, Madrid
2026-04-08
Recruiting
Pfizer
Phase 1/2
132
Barcelona, Santander, Madrid, Seville
2026-03-11
Active, closed
Pfizer
Phase 3
1,078
Málaga, Barcelona, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia
2026-02-24
Recruiting
Pfizer
Phase 1/2
224
Barcelona, Málaga, Madrid
2026-02-10
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Jaén, Barcelona, Jerez de la Frontera, Madrid, Málaga, Valencia, Cadiz, Granada
2026-01-30
Active, closed
Pfizer
Phase 3
3,578
Málaga, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia
2025-12-19
Recruiting
Pfizer
Phase 3
800
Santiago de Compostela, Málaga, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Madrid, Córdoba, Valencia
2025-12-11
Recruiting
Pfizer
Phase 2/3
550
Jaén, Jerez de la Frontera, Madrid, Barcelona
2025-12-09
Active, closed
Pfizer
Phase 2
128
Manises, Cadiz, Granada, Madrid, Pontevedra
2025-11-13
Active, closed
Pfizer
Phase 2
42
Madrid
2025-11-10
Recruiting
Pfizer
Phase 1
294
Madrid
2025-11-06
Recruiting
Pfizer
Phase 2/3
982
Barcelona, Madrid, Oviedo, Málaga
2025-10-03
Recruiting
Pfizer
Phase 3
680
A Coruña, Badalona, Barcelona, Madrid, Badajoz, Granada, Palma, Seville
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Barcelona, Madrid, Vigo, Valencia
2025-09-28
Recruiting
Pfizer
Phase 3
6,000
Santiago de Compostela, Esplugues de Llobregat, Pozuelo de Alarcón, Torrejón de Ardoz, Madrid, Antequera, Aravaca, Seville
2025-08-25
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
Barcelona, Madrid
2025-08-20
Recruiting
Pfizer
Phase 3
714
A Coruña, Elche, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Palma, Madrid, Valencia
2025-07-23
Recruiting
Pfizer
Phase 3
300
A Coruña, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante, Seville
2025-07-14
Active, closed
Pfizer
Phase 1/2
74
Barcelona, Madrid, Málaga, Valencia, Granada
2025-06-30
Recruiting
Pfizer
Phase 2
620
Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid, Valencia
2025-06-19
Recruiting
Pfizer
Phase 2
252
Santander, Madrid, Pozuelo de Alarcón, Málaga
2025-05-20
Recruiting
Pfizer
Phase 3
674
Santiago de Compostela, Córdoba, Madrid, Zaragoza
2025-04-01
Recruiting
Pfizer
Phase 3
723
Barcelona, Santander, Chiclana de la Frontera, Madrid, Seville, Valladolid, Zaragoza
2025-03-11
Recruiting
Pfizer
Phase 3
2,330
A Coruña, Benalmádena, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante
2024-12-08
Active, closed
Pfizer
Phase 3
200
Barcelona, Madrid, Vigo, Seville, Valencia, Valladolid
2024-11-15
Recruiting
Pfizer
Phase 3
900
L'Hospitalet de Llobregat, Madrid, Valencia
2024-10-22
Active, closed
Pfizer
Phase 3
600
L'Hospitalet de Llobregat, Barcelona, Madrid, Manresa, Valencia
2024-10-21
Recruiting
Pfizer
Phase 2
48
Madrid
2024-09-25
Active, closed
Pfizer
Phase 1/2
71
Barcelona, Lleida, Madrid, Seville
2024-02-19
Recruiting
Pfizer
Phase 3
492
Badalona, Terrassa, Barakaldo, Barcelona, Murcia, Girona, Valencia, Madrid
2024-02-08
Active, closed
Pfizer
Phase 3
394
Córdoba, Barcelona, Las Palmas de Gran Canaria, Madrid
2024-01-19
Active, closed
Pfizer
Phase 3
1,571
Córdoba, Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Barcelona, Valencia, Zaragoza
2023-11-08
Active, closed
Pfizer
Phase 3
59
Badalona, Barcelona, Jaén, Málaga, Granada, Madrid
2023-08-09
Recruiting
Pfizer
Phase 3
318
Madrid, San Cristóbal de La Laguna
2023-05-20
Recruiting
Pfizer
Phase 2
100
Santiago de Compostela, Barcelona, Esplugues de Llobregat, Madrid, El Palmar, Seville, Valencia
2023-05-17
Recruiting
Pfizer
Phase 2
48
Badalona, Esplugues de Llobregat, Madrid, Barcelona
2023-04-18
Active, closed
Pfizer
Phase 1/2
20
Madrid, Seville
2023-03-01
Active, closed
Pfizer
Phase 1/2
37
Barcelona, Madrid, Pamplona, Seville
2023-02-23
Recruiting
Pfizer
Phase 3
100
Madrid, Zaragoza
2022-12-09
Recruiting
Pfizer
Phase 3
1,060
Santiago de Compostela, Badalona, L'Hospitalet Del Llobregat, Terrassa, Santander, Barcelona, Girona, Madrid
2022-11-10
Recruiting
Pfizer
Observational
12,500
L'Hospitalet de Llobregat, Getafe, Leganés, Vigo, Valencia, Barcelona, Madrid, Málaga
2022-10-27
Active, closed
Pfizer
Phase 2
108
Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia, Zaragoza
2022-07-11
Recruiting
Pfizer
Phase 4
210
A Coruña, Badalona, Barcelona, Santander, Lleida, Majadahonda, Madrid, Málaga
2022-07-05
Active, closed
Pfizer
Phase 3
854
Santiago de Compostela, Barcelona, L'Hospitalet Del Llobregat, Terrassa, Badalona, Salamanca, Pozuelo de Alarcón, Madrid
2022-03-25
Active, closed
Pfizer
Phase 1/2
235
Barcelona, Madrid, Seville
2022-03-14
Recruiting
Pfizer
Phase 3
640
Sabadell, Valladolid, Vigo, Valencia, Madrid, Seville
2022-02-28
Recruiting
Pfizer
Phase 3
245
A Coruña, Barcelona, Madrid, Zaragoza
2021-11-17
Active, closed
Pfizer
Phase 3
77
Barcelona, L'Hospitalet de Llobregat, Madrid, Seville
2021-09-29
Active, closed
Pfizer
Phase 2
187
Madrid, Valencia
2021-02-02
Recruiting
Pfizer
Phase 3
2,100
Santander, Barcelona, Madrid, Seville, Valladolid
2021-01-15
Active, closed
Pfizer
Phase 3
841
Santiago de Compostela, Elche, L'Hospitalet de Llobregat, Barcelona, Madrid, Seville, Valencia, Zaragoza
2020-12-21
Active, closed
Pfizer
Phase 3
896
Alicante, Madrid
2019-09-05
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
L'Hospitalet de Llobregat, Castellon, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Valencia
2018-04-17
Active, closed
Pfizer
Phase 3
1,054
Santiago de Compostela, Elche, L'Hospitalet de Llobregat, Sabadell, El Palmar, Barcelona, Madrid
2017-12-18
Active, closed
Pfizer
Phase 3
296
L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Majadahonda, Pamplona, A Coruña, Barcelona, Girona, Madrid
2017-04-27
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Palma de Mallorca, Manresa, Santiago de Compostela, Barcelona, Cadiz, Girona, Madrid, Ourense
2014-12-17
Rows per page Showing 1–59 of 59
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/madrid

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 59 of those studies with a site in Madrid that also match the filters currently applied.

How many clinical trials are recruiting in Madrid?

36 of the 59 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Madrid), 59 studies
PhaseStudiesRecruitingShare
Phase 3321854.2%
Phase 210616.9%
Phase 1/28313.6%
Phase 1446.8%
Phase 2/3335.1%
Observational111.7%
Phase 4111.7%

Most active sponsors

Lead sponsors with the most studies (Madrid)
Lead sponsorStudiesRecruiting
Pfizer5936
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.